

Leonard H Rome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2986937/publications.pdf>

Version: 2024-02-01

115
papers

8,055
citations

57758

44
h-index

49909

87
g-index

115
all docs

115
docs citations

115
times ranked

7040
citing authors

#	ARTICLE	IF	CITATIONS
1	Decolorization and detoxification of synthetic dye compounds by laccase immobilized in vault nanoparticles. <i>Bioresource Technology</i> , 2022, 351, 127040.	9.6	22
2	Immobilized fungal enzymes: Innovations and potential applications in biodegradation and biosynthesis. <i>Biotechnology Advances</i> , 2022, 57, 107936.	11.7	23
3	Immunoediting role for major vault protein in apoptotic signaling induced by bacterial <i>N</i> -acyl homoserine lactones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	11
4	Vault nanocapsule-mediated biomimetic silicification for efficient and robust immobilization of proteins in silica composites. <i>Chemical Engineering Journal</i> , 2021, 418, 129406.	12.7	9
5	Vault packaged enzyme mediated degradation of amino-aromatic energetic compounds. <i>Chemosphere</i> , 2020, 242, 125117.	8.2	11
6	Bioengineered recombinant vault nanoparticles coupled with NY-ESO-1 glioma-associated antigens induce maturation of native dendritic cells. <i>Journal of Neuro-Oncology</i> , 2020, 148, 1-7.	2.9	7
7	Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma. <i>Journal of Neuro-Oncology</i> , 2020, 147, 599-605.	2.9	21
8	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. <i>Bioconjugate Chemistry</i> , 2019, 30, 2216-2227.	3.6	13
9	Reassessment of Exosome Composition. <i>Cell</i> , 2019, 177, 428-445.e18.	28.9	1,786
10	A Vault-Encapsulated Enzyme Approach for Efficient Degradation and Detoxification of Bisphenol A and Its Analogues. <i>ACS Sustainable Chemistry and Engineering</i> , 2019, 7, 5808-5817.	6.7	28
11	Solution Structures of Engineered Vault Particles. <i>Structure</i> , 2018, 26, 619-626.e3.	3.3	14
12	Synthesis and assembly of human vault particles in yeast. <i>Biotechnology and Bioengineering</i> , 2018, 115, 2941-2950.	3.3	14
13	Encapsulation of Exogenous Proteins in Vault Nanoparticles. <i>Methods in Molecular Biology</i> , 2018, 1798, 25-37.	0.9	4
14	Vault Nanoparticles: Chemical Modifications for Imaging and Enhanced Delivery. <i>ACS Nano</i> , 2017, 11, 872-881.	14.6	30
15	Modulation of the Vault Protein-Protein Interaction for Tuning of Molecular Release. <i>Scientific Reports</i> , 2017, 7, 14816.	3.3	8
16	A Protective Vaccine against Chlamydia Genital Infection Using Vault Nanoparticles without an Added Adjuvant. <i>Vaccines</i> , 2017, 5, 3.	4.4	26
17	Vault Nanoparticles Packaged with Enzymes as an Efficient Pollutant Biodegradation Technology. <i>ACS Nano</i> , 2015, 9, 10931-10940.	14.6	49
18	Dual pH- and temperature-responsive protein nanoparticles. <i>European Polymer Journal</i> , 2015, 69, 532-539.	5.4	31

#	ARTICLE	IF	CITATIONS
19	Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope. <i>Vaccine</i> , 2015, 33, 298-306.	3.8	21
20	Polyribosomes Are Molecular 3D Nanoprinters That Orchestrate the Assembly of Vault Particles. <i>ACS Nano</i> , 2014, 8, 11552-11559.	14.6	35
21	Bioengineered Vaults: Self-Assembling Protein Shell Lipophilic Core Nanoparticles for Drug Delivery. <i>ACS Nano</i> , 2014, 8, 7723-7732.	14.6	54
22	Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 151-158.	1.3	15
23	Development of the Vault Particle as a Platform Technology. <i>ACS Nano</i> , 2013, 7, 889-902.	14.6	75
24	Smart Vaults: Thermally-Responsive Protein Nanocapsules. <i>ACS Nano</i> , 2013, 7, 867-874.	14.6	59
25	CCL21 Chemokine Therapy for Lung Cancer. <i>International Trends in Immunity</i> , 2013, 1, 10-15.	0.4	8
26	198 An Antigen Vault Nanoparticle Vaccine Can Effectively Stimulate Dendritic Cells and Activate a Specific T cell Immune Response. <i>Neurosurgery</i> , 2012, 71, E576-E577.	1.1	0
27	Vault Nanocapsules as Adjuvants Favor Cell-Mediated over Antibody-Mediated Immune Responses following Immunization of Mice. <i>PLoS ONE</i> , 2012, 7, e38553.	2.5	35
28	Targeted Vault Nanoparticles Engineered with an Endosomolytic Peptide Deliver Biomolecules to the Cytoplasm. <i>ACS Nano</i> , 2011, 5, 6128-6137.	14.6	43
29	Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth. <i>PLoS ONE</i> , 2011, 6, e18758.	2.5	93
30	Vaults Engineered for Hydrophobic Drug Delivery. <i>Small</i> , 2011, 7, 1432-1439.	10.0	41
31	Drug Delivery: Vaults Engineered for Hydrophobic Drug Delivery (<i>Small</i> 10/2011). <i>Small</i> , 2011, 7, 1431-1431.	10.0	0
32	Vaults Are Dynamically Unconstrained Cytoplasmic Nanoparticles Capable of Half Vault Exchange. <i>ACS Nano</i> , 2010, 4, 7229-7240.	14.6	27
33	Immobilization of Recombinant Vault Nanoparticles on Solid Substrates. <i>ACS Nano</i> , 2010, 4, 1417-1424.	14.6	16
34	Nucleic acid nanocapsules: packaging mRNA into the vault particle. <i>FASEB Journal</i> , 2010, 24, 886.1.	0.5	0
35	Structural Stability of Vault Particles. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1376-1386.	3.3	32
36	Vault Nanoparticles Containing an Adenovirus-Derived Membrane Lytic Protein Facilitate Toxin and Gene Transfer. <i>ACS Nano</i> , 2009, 3, 691-699.	14.6	40

#	ARTICLE	IF	CITATIONS
37	Targeting Vault Nanoparticles to Specific Cell Surface Receptors. ACS Nano, 2009, 3, 27-36.	14.6	92
38	Utilization of a Protein "Shuttle" To Load Vault Nanocapsules with Gold Probes and Proteins. ACS Nano, 2009, 3, 3175-3183.	14.6	38
39	A Vault Nanoparticle Vaccine Induces Protective Mucosal Immunity. PLoS ONE, 2009, 4, e5409.	2.5	98
40	Particles slip cell security. Nature Materials, 2008, 7, 519-520.	27.5	43
41	Encapsulation of Semiconducting Polymers in Vault Protein Cages. Nano Letters, 2008, 8, 3503-3509.	9.1	31
42	Reversible pH Lability of Cross-linked Vault Nanocapsules. Nano Letters, 2008, 8, 3510-3515.	9.1	19
43	Draft Crystal Structure of the Vault Shell at 9-Å... Resolution. PLoS Biology, 2007, 5, e318.	5.6	43
44	Vault Nanocapsule Dissociation into Halves Triggered at Low pH. Biochemistry, 2007, 46, 2865-2875.	2.5	39
45	Sizing large proteins and protein complexes by electrospray ionization mass spectrometry and ion mobility. Journal of the American Society for Mass Spectrometry, 2007, 18, 1206-1216.	2.8	141
46	The Vault Exterior Shell Is a Dynamic Structure that Allows Incorporation of Vault-Associated Proteins into Its Interior. Biochemistry, 2006, 45, 12184-12193.	2.5	58
47	Movement of vault particles visualized by GFP-tagged major vault protein. Cell and Tissue Research, 2006, 324, 403-410.	2.9	18
48	Minimizing the VPARP MVP interaction domain and implications in engineering new vault function. FASEB Journal, 2006, 20, LB60.	0.5	0
49	Nuclear localization of the major vault protein in U373 cells. Cell and Tissue Research, 2005, 321, 97-104.	2.9	25
50	Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4348-4352.	7.1	123
51	Increased Susceptibility of Vault Poly(ADP-Ribose) Polymerase-Deficient Mice to Carcinogen-Induced Tumorigenesis. Cancer Research, 2005, 65, 8846-8852.	0.9	47
52	The p80 homology region of TEP1 is sufficient for its association with the telomerase and vault RNAs, and the vault particle. Nucleic Acids Research, 2005, 33, 893-902.	14.5	28
53	Vault Poly(ADP-Ribose) Polymerase Is Associated with Mammalian Telomerase and Is Dispensable for Telomerase Function and Vault Structure In Vivo. Molecular and Cellular Biology, 2004, 24, 5314-5323.	2.3	50
54	Analysis of MVP and VPARP promoters indicates a role for chromatin remodeling in the regulation of MVP. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1678, 33-46.	2.4	7

#	ARTICLE	IF	CITATIONS
55	Cryoelectron Microscopy Imaging of Recombinant and Tissue Derived Vaults: Localization of the MVP N Termini and VPARP. <i>Journal of Molecular Biology</i> , 2004, 344, 91-105.	4.2	85
56	Identification of conserved vault RNA expression elements and a non-expressed mouse vault RNA gene. <i>Gene</i> , 2003, 309, 65-70.	2.2	28
57	The La RNA-binding Protein Interacts with the Vault RNA and Is a Vault-associated Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 41282-41286.	3.4	37
58	A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. <i>International Journal of Cancer</i> , 2002, 97, 149-156.	5.1	31
59	Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. <i>International Journal of Cancer</i> , 2001, 92, 195-202.	5.1	80
60	The Telomerase/Vault-Associated Protein Tep1 Is Required for Vault RNA Stability and Its Association with the Vault Particle. <i>Journal of Cell Biology</i> , 2001, 152, 157-164.	5.2	73
61	Assembly of Vault-like Particles in Insect Cells Expressing Only the Major Vault Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 23217-23220.	3.4	120
62	RNA location and modeling of a WD40 repeat domain within the vault. <i>Rna</i> , 2000, 6, 890-900.	3.5	66
63	Analysis of sulfatide from rat cerebellum and multiple sclerosis white matter by negative ion electrospray mass spectrometry. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1484, 59-70.	2.4	54
64	Vaults and Telomerase Share a Common Subunit, TEP1. <i>Journal of Biological Chemistry</i> , 1999, 274, 32712-32717.	3.4	128
65	Recombinant Major Vault Protein Is Targeted to Neuritic Tips of PC12 Cells. <i>Journal of Cell Biology</i> , 1999, 144, 1163-1172.	5.2	53
66	The 193-Kd Vault Protein, Vparp, Is a Novel Poly(Adp-Ribose) Polymerase. <i>Journal of Cell Biology</i> , 1999, 146, 917-928.	5.2	355
67	Structure of the vault, a ubiquitous cellular component. <i>Structure</i> , 1999, 7, 371-379.	3.3	114
68	Cloning of a cDNA encoding a sequence-specific single-stranded-DNA-binding protein from <i>Rattus norvegicus</i> . <i>Gene</i> , 1999, 237, 201-207.	2.2	5
69	Role of axonal components during myelination. <i>Microscopy Research and Technique</i> , 1998, 41, 379-392.	2.2	18
70	Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 1998, 273, 8971-8974.	3.4	207
71	Axonal Proteins Involved in Myelination: Characterization of a Collagen-Like Protein. <i>Developmental Neuroscience</i> , 1997, 19, 421-429.	2.0	5
72	Vaults are the answer, what is the question?. <i>Trends in Cell Biology</i> , 1996, 6, 174-178.	7.9	71

#	ARTICLE	IF	CITATIONS
73	Relationship of LRP-human major vault protein toin vitro and clinical resistance to anticancer drugs. Cytotechnology, 1996, 19, 191-197.	1.6	49
74	Multidrug resistance: Locked in the vault?. Nature Medicine, 1995, 1, 527-527.	30.7	3
75	Dictyostelium Vaults: Disruption of the Major Proteins Reveals Growth and Morphological Defects and Uncovers a New Associated Protein. Journal of Biological Chemistry, 1995, 270, 16588-16594.	3.4	46
76	Cloning and sequence of the cDNA encoding the rat oligodendrocyte integrin β 1 subunit. Gene, 1995, 158, 287-290.	2.2	14
77	Expression of a beta 1-related integrin by oligodendroglia in primary culture: evidence for a functional role in myelination. Journal of Cell Biology, 1994, 124, 1039-1046.	5.2	48
78	Stimulation of in vitro myelin synthesis by microglia. Glia, 1994, 11, 326-335.	4.9	97
79	The sequence of a cDNA encoding the major vault protein from Rattus norvegicus. Gene, 1994, 151, 257-260.	2.2	45
80	Functional evidence for the role of axolemma in CNS myelination. Neuron, 1994, 13, 473-485.	8.1	39
81	A Protein Involved in Central Nervous System Myelination: Localization in the Extracellular Matrix and Induction in Neuroblastoma Cells. Developmental Neuroscience, 1994, 16, 267-278.	2.0	6
82	Myelination in cerebellar slice cultures: Development of a system amenable to biochemical analysis. Journal of Neuroscience Research, 1993, 36, 621-634.	2.9	63
83	Expression of multiple integrins and extracellular matrix components by C6 glioma cells. Journal of Neuroscience Research, 1992, 31, 470-478.	2.9	17
84	Immunolocalization of vault particles in cultured cells. Proceedings Annual Meeting Electron Microscopy Society of America, 1992, 50, 458-459.	0.0	0
85	Unlocking vaults: organelles in search of a function. Trends in Cell Biology, 1991, 1, 47-50.	7.9	112
86	Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry.. Journal of Cell Biology, 1991, 112, 225-235.	5.2	161
87	Vaults: Large cytoplasmic RNP's that associate with cytoskeletal elements. Molecular Biology Reports, 1990, 14, 121-122.	2.3	29
88	Glass microâ€¢fibers: A model system for study of early events in myelination. Journal of Neuroscience Research, 1990, 27, 383-393.	2.9	20
89	Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes.. Journal of Cell Biology, 1990, 110, 895-901.	5.2	143
90	Matrix Interactions Regulating Myelinogenesis in Cultured Oligodendrocytes. Advances in Experimental Medicine and Biology, 1990, 265, 157-167.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Cation-independent mannose 6-phosphate receptor contains covalently bound fatty acid. <i>Journal of Cellular Biochemistry</i> , 1988, 38, 23-33.	2.6	18
92	Evidence that an RGD-dependent receptor mediates the binding of oligodendrocytes to a novel ligand in a glial-derived matrix.. <i>Journal of Cell Biology</i> , 1988, 107, 1541-1549.	5.2	39
93	RGD-containing peptides inhibit the synthesis of myelin-like membrane by cultured oligodendrocytes.. <i>Journal of Cell Biology</i> , 1988, 107, 1551-1559.	5.2	45
94	Lysosomal enzyme precursors in coated vesicles derived from the exocytic and endocytic pathways.. <i>Journal of Cell Biology</i> , 1987, 104, 1743-1748.	5.2	67
95	Preparative agarose gel electrophoresis for the purification of small organelles and particles. <i>Analytical Biochemistry</i> , 1986, 156, 161-170.	2.4	39
96	Synthesis of a myelin-like membrane by oligodendrocytes in culture. <i>Journal of Neuroscience Research</i> , 1986, 15, 49-65.	2.9	76
97	Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA.. <i>Journal of Cell Biology</i> , 1986, 103, 699-709.	5.2	287
98	Genetic evidence for transmembrane acetylation by lysosomes. <i>Science</i> , 1986, 233, 1087-1089.	12.6	32
99	Subpopulations of liver coated vesicles resolved by preparative agarose gel electrophoresis.. <i>Journal of Cell Biology</i> , 1986, 103, 287-297.	5.2	35
100	Binding and internalization of lysosomal enzymes by primary cultures of rat glia. <i>Journal of Neuroscience Research</i> , 1985, 14, 35-47.	2.9	13
101	Curling receptors. <i>Trends in Biochemical Sciences</i> , 1985, 10, 151.	7.5	20
102	Interaction of rat liver lysosomal membranes with actin.. <i>Journal of Cell Biology</i> , 1984, 99, 680-685.	5.2	21
103	Lysosomal function in the degradation of defective collagen in cultured lung fibroblasts. <i>Biochemistry</i> , 1984, 23, 2134-2138.	2.5	33
104	[52] $\hat{1}\pm$ -l-iduronidase from human kidney. <i>Methods in Enzymology</i> , 1982, 83, 578-582.	1.0	6
105	[53] Uptake and binding of $\hat{1}\pm$ -l-iduronidase. <i>Methods in Enzymology</i> , 1982, 83, 582-587.	1.0	0
106	Assay and purification of a solubilized membrane receptor that binds the lysosomal enzyme $\hat{1}\pm$ -l-iduronidase. <i>Archives of Biochemistry and Biophysics</i> , 1982, 214, 681-687.	3.0	79
107	Butanedione treatment reduces receptor binding of a lysosomal enzyme to cells and membranes. <i>Biochemical and Biophysical Research Communications</i> , 1980, 92, 986-993.	2.1	41
108	Two species of lysosomal organelles in cultured human fibroblasts. <i>Cell</i> , 1979, 17, 143-153.	28.9	378

#	ARTICLE	IF	CITATIONS
109	Direct demonstration of binding of a lysosomal enzyme, alpha-L-iduronidase, to receptors on cultured fibroblasts.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 2331-2334.	7.1	140
110	Human kidney α -L-Iduronidase: Purification and characterization. Archives of Biochemistry and Biophysics, 1978, 189, 344-353.	3.0	54
111	The transport of lysosomal enzymes. Journal of Supramolecular Structure, 1977, 6, 95-101.	2.3	208
112	Aspirin as a quantitative acetylating reagent for the fatty acid oxygenase that forms prostaglandins. Prostaglandins, 1976, 11, 23-30.	1.2	74
113	Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs.. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72, 4863-4865.	7.1	286
114	Properties of a partially-purified preparation of the prostaglandin-forming oxygenase from sheep vesicular gland. Prostaglandins, 1975, 10, 813-824.	1.2	37
115	Solution Structures of Engineered Vault Particles. SSRN Electronic Journal, 0, , .	0.4	0